Showing results (211-220 of 286) with videos related to
Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.Cancer Journal (Sudbury, Mass.)|January 22, 2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United StatesLawrence Flaherty, Omid Hamid, Gerald Linette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaPaolo A Ascierto, David Minor, Antoni Ribas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 StudyTheresa Medina, Jason A Chesney, Harriet M Kluger, et al.The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2015
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerRyan B Corcoran, Chloe E Atreya, Gerald S Falchook, et al.JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.European Journal of Cancer (Oxford, England : 1990)|September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanomaOmid Hamid, Igor Puzanov, Reinhard Dummer, et al.Journal for Immunotherapy of Cancer|October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumorsOmid Hamid, Alberto A Chiappori, John A Thompson, et al.Pageof 29